4.6 Article

First-trimester screening for Down syndrome using quadruple maternal biochemical markers

期刊

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 61, 期 9, 页码 1630-1635

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2022-1305

关键词

biomarkers; Down syndrome; nuchal translucency; pregnancy; ultrasound

向作者/读者索取更多资源

The combination of maternal markers PAPP-A, free beta-hCG, PlGF and AFP has demonstrated a predictive value in Down syndrome screening. Adding nuchal translucency further increases the detection rate to above 95% with a false-positive rate below 5%.
Objectives: Placental growth factor (PlGF) is used for first-trimester preeclampsia screening and could be combined with other biochemical markers for Down syndrome screening. We aim to estimate the predictive value of the combination of pregnancy-associated plasma protein (PAPP-A), free beta-human chorionic gonadotropin (free beta-hCG), placental growth factor (PlGF) and alpha-fetoprotein (AFP) with and without nuchal translucency. Methods: Singleton pregnancies recruited at 11-14 weeks and followed until delivery. The four maternal markers were measured using Kryptor (ThermoFisher-BRAHMS) and adjusted for gestational age and maternal characteristics. The risk of Down syndrome was calculated using the Fetal Medicine Foundation algorithm and multivariate linear regression analyses in all cases and in 2,200 controls. Receiver-operator characteristic (ROC) curves were used to calculate the detection and false-positive rates. Results: Twenty-six (0.2%) cases of Down syndrome were diagnosed among 13,386 participants. The combination of the four biomarkers could have detected 88% (95% CI: 72-97%) of the cases at a false-positive rate of 13% (95% CI: 12-15%). The addition of nuchal translucency would have increased the detection rate to 96% (95% CI: 82-99%) at a false-positive rate of 4% (95% CI: 4-5%) using a 1:300 cut-off and to 100% (95% CI: 89-100%) at a false-positive rate of 6% (95% CI: 5-8%) using a 1:500 cut-off. Conclusions: First-trimester screening using biochemical markers allows the identification of approximately 88% of Down syndrome cases for a false-positive rate of 13%. The addition of nuchal translucency raises the detection rate above 95% with a false-positive rate below 5%.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据